slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 61,111-61,140
Pages 3,679
Rows per page 30
Component
61,111-61,140 of 110,355
04
The chart uses a gradient arrow to emphasize the scale of 12.2M participants compared to other biobanks.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
05
The slide uses a split-screen layout with a quote on the left and quantitative evidence on the right.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
07
The slide uses a timeline format to demonstrate regulatory milestones and credibility.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
08
The slide combines quantitative traction metrics with a qualitative customer story to validate the product's value proposition.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
09
The slide uses a DNA-themed background with scattered A, T, C, G letters.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
19
The chart highlights that health care only accounts for 10% of the risk of premature death, framing the opportunity for non-clinical interventions.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
20
The slide uses a gradient color scheme for the bars. The data is sourced from a 2019 survey of 1,046 customers.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
22
Uses a simple equation-style visual to show the merger/partnership of two entities resulting in a set of service offerings.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
27
The slide uses a split-screen layout with a blue background on the left for the core problem statement and a white background on the right for supporting metrics.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
28
The slide uses a contrast-pair framework to highlight the competitive advantage of 23andMe over the traditional industry.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
31
The slide uses Manhattan plots to show genetic association density over time and a line chart to show the cumulative growth of independent hits.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
36
The slide uses a timeline-style layout to show drug development stages from Discovery to Phase 2.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
38
The slide uses a three-column process flow to connect market opportunity, genetic validation, and biological mechanism.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
40
The chart shows tumor growth inhibition over time, highlighting the triple combination (Anti-CD96 + Anti-TIGIT + Anti-PD1) as the most effective.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
10
The slide emphasizes exclusivity in the development pipeline for both modalities.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · Solution1 hit
19
The slide uses box plots to compare control vs mVGL101 groups across six different gene expression categories.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · Solution1 hit
23
The slide uses a 2x2 grid layout to categorize disease information.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
24
The diagram shows the molecular mechanism of cell signaling across the cell membrane.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
25
The slide uses a comparison matrix to establish a biological rationale for targeting these pathways.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
26
The slide uses a causal chain diagram to link genetic mutations to cellular outcomes, supported by empirical data from Kempthorne et al. 2020.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
29
Scientific slide presenting microscopy and imaging data (A-D) to support a mechanism of action.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
30
The slide uses a combination of longitudinal imaging and scatter/dot plots to establish clinical validity for biomarkers.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
31
The diagram uses a network-style flow to show how early-stage research and patient engagement feed into later-stage clinical trials.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
34
The slide uses a top-down funnel approach to narrow the market from general leukodystrophies to the specific ALSP indication.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank Beat · Market Size1 hit
39
The data highlights the specificity of the drug candidate for brain tissue over peripheral circulation.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
44
Includes a Manhattan plot (GWAS) and immunohistochemistry images with quantitative analysis of microglia clustering.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
45
Slide contains multiple microscopy images and bar charts showing experimental results from Yuan et al (2016) and Wang et al (2020).Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
46
The slide presents histological images and quantitative dot plots comparing Trem2 wild-type, heterozygous, and knockout mice.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
49
The slide uses a structured matrix to justify pipeline expansion by highlighting significant unmet medical needs across three rare diseases.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit
50
The slide uses a causal chain diagram to explain the disease progression and a biological process diagram to explain the therapeutic intervention.Vigil Neuroscience | IPO Presentation Deck | 54 slides · Vigil Neuroscience
Pitch deck Investment bank 1 hit